Patents by Inventor Denise Demarais
Denise Demarais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8454594Abstract: Methods and apparatus are provided for non-continuous circumferential treatment of a body lumen. Apparatus may be positioned within a body lumen of a patient and may deliver energy at a first lengthwise and angular position to create a less-than-full circumferential treatment zone at the first position. The apparatus also may deliver energy at one or more additional lengthwise and angular positions within the body lumen to create less-than-full circumferential treatment zone(s) at the one or more additional positions that are offset lengthwise and angularly from the first treatment zone. Superimposition of the first treatment zone and the one or more additional treatment zones defines a non-continuous circumferential treatment zone without formation of a continuous circumferential lesion. Various embodiments of methods and apparatus for achieving such non-continuous circumferential treatment are provided.Type: GrantFiled: August 11, 2009Date of Patent: June 4, 2013Assignee: Medtronic Ardian Luxembourg S.a.r.l.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Nicolas Zadno, Benjamin J. Clark, Andrew Wu, Kenneth J. Michlitsch
-
Patent number: 8444640Abstract: Methods and apparatus are provided for non-continuous circumferential treatment of a body lumen. Apparatus may be positioned within a body lumen of a patient and may deliver energy at a first lengthwise and angular position to create a less-than-full circumferential treatment zone at the first position. The apparatus also may deliver energy at one or more additional lengthwise and angular positions within the body lumen to create less-than-full circumferential treatment zone(s) at the one or more additional positions that are offset lengthwise and angularly from the first treatment zone. Superimposition of the first treatment zone and the one or more additional treatment zones defines a non-continuous circumferential treatment zone without formation of a continuous circumferential lesion. Various embodiments of methods and apparatus for achieving such non-continuous circumferential treatment are provided.Type: GrantFiled: September 14, 2012Date of Patent: May 21, 2013Assignee: Medtronic Ardian Luxembourg S.a.r.l.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Nicolas Zadno, Benjamin J. Clark, Andrew Wu, Kenneth J. Michlitsch
-
Publication number: 20130116685Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.Type: ApplicationFiled: September 14, 2012Publication date: May 9, 2013Applicant: Ardian, Inc.Inventors: Mark Deem, Hanson Gifford, III, Denise Demarais, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
-
Patent number: 8433423Abstract: Methods and apparatus are provided for multi-vessel neuromodulation, e.g., via a pulsed electric field. Such multi-vessel neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, the multi-vessel neuromodulation is applied to neural fibers that contribute to renal function. Such multi-vessel neuromodulation optionally may be performed bilaterally.Type: GrantFiled: December 13, 2010Date of Patent: April 30, 2013Assignee: Ardian, Inc.Inventor: Denise Demarais
-
Patent number: 8398630Abstract: Methods and apparatus are provided for non-continuous circumferential treatment of a body lumen. Apparatus may be positioned within a body lumen of a patient and may deliver energy at a first lengthwise and angular position to create a less-than-full circumferential treatment zone at the first position. The apparatus also may deliver energy at one or more additional lengthwise and angular positions within the body lumen to create less-than-full circumferential treatment zone(s) at the one or more additional positions that are offset lengthwise and angularly from the first treatment zone. Superimposition of the first treatment zone and the one or more additional treatment zones defines a non-continuous circumferential treatment zone without formation of a continuous circumferential lesion. Various embodiments of methods and apparatus for achieving such non-continuous circumferential treatment are provided.Type: GrantFiled: September 14, 2012Date of Patent: March 19, 2013Assignee: Medtronic Ardian Luxembourg S.a.r.l.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Nicolas Zadno, Benjamin J. Clark, Andrew Wu, Kenneth J. Michlitsch
-
Publication number: 20130012867Abstract: Methods and apparatus are provided for non-continuous circumferential treatment of a body lumen. Apparatus may be positioned within a body lumen of a patient and may deliver energy at a first lengthwise and angular position to create a less-than-full circumferential treatment zone at the first position. The apparatus also may deliver energy at one or more additional lengthwise and angular positions within the body lumen to create less-than-full circumferential treatment zone(s) at the one or more additional positions that are offset lengthwise and angularly from the first treatment zone. Superimposition of the first treatment zone and the one or more additional treatment zones defines a non-continuous circumferential treatment zone without formation of a continuous circumferential lesion. Various embodiments of methods and apparatus for achieving such non-continuous circumferential treatment are provided.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Nicolas Zadno, Benjamin J. Clark, Andrew Wu, Kenneth J. Michlitsch
-
Publication number: 20130012844Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Ardian, Inc.Inventors: Denise Demarais, Nicolas Zadno, Benjamin J. Clark, Erik Thai, Howard R. Levin, Mark Gelfand
-
Publication number: 20130012866Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Ardian, Inc.Inventors: Mark Deem, Hanson Gifford, III, Denise Demarais, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
-
Patent number: 8347891Abstract: Methods and apparatus are provided for non-continuous circumferential treatment of a body lumen. Apparatus may be positioned within a body lumen of a patient and may deliver energy at a first lengthwise and angular position to create a less-than-full circumferential treatment zone at the first position. The apparatus also may deliver energy at one or more additional lengthwise and angular positions within the body lumen to create less-than-full circumferential treatment zone(s) at the one or more additional positions that are offset lengthwise and angularly from the first treatment zone. Superimposition of the first treatment zone and the one or more additional treatment zones defines a non-continuous circumferential treatment zone without formation of a continuous circumferential lesion. Various embodiments of methods and apparatus for achieving such non-continuous circumferential treatment are provided.Type: GrantFiled: November 14, 2006Date of Patent: January 8, 2013Assignee: Medtronic Ardian Luxembourg S.a.r.l.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Nicolas Zadno, Benjamin J. Clark, Andrew Wu, Kenneth J. Michlitsch
-
Publication number: 20120283699Abstract: Clot disruption and dissolution are achieved using a catheter having the ability to infuse a thrombolytic agent, aspirate clot and fluid, and allow passage of a guidewire. Optionally, the catheter may also include a mechanical agitator for further disrupt clot in the presence of the thrombolytic agent. A flow resistor in the catheter provides for infusion and/or aspiration to be concentrated primarily at a clot treatment area in a blood vessel while also providing optional infusion and/or aspiration distal to the treatment area. In some embodiments, infusion, aspiration and guidewire passage occur through a common lumen. The thrombolytic agent, such as tPA, streptokinase, or urokinase, is directly released into the clot at the point where the agitator is engaging the clot. In this way, the thrombolytic activity of the agent is enhanced and the dissolution of the clot is improved.Type: ApplicationFiled: July 13, 2012Publication date: November 8, 2012Applicant: TYCO HEALTHCARE GROUP LPInventors: Michael A. Evans, Denise Demarais, Dino De Cicco, Kelvin Ning, Alexander Khairkhahan, Tyler Jon Strang
-
Publication number: 20120197252Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.Type: ApplicationFiled: January 30, 2012Publication date: August 2, 2012Applicant: Ardian, Inc.Inventors: Mark Deem, Denise Demarais, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
-
Publication number: 20120197198Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: January 30, 2012Publication date: August 2, 2012Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
-
Publication number: 20120172837Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.Type: ApplicationFiled: March 9, 2012Publication date: July 5, 2012Applicant: Ardian, Inc.Inventors: Denise Demarais, Nicolas Zadno, Benjamin J. Clark, Erik Thai, Howard R. Levin, Mark Gelfand
-
Publication number: 20120143181Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.Type: ApplicationFiled: February 10, 2012Publication date: June 7, 2012Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
-
Publication number: 20120130289Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: ApplicationFiled: January 30, 2012Publication date: May 24, 2012Applicant: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
-
Patent number: 8175711Abstract: Methods and apparatus are provided for treating congestive heart failure, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: GrantFiled: March 6, 2006Date of Patent: May 8, 2012Assignee: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
-
Patent number: 8150519Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: GrantFiled: March 6, 2006Date of Patent: April 3, 2012Assignee: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
-
Patent number: 8150520Abstract: Methods and apparatus are provided for treating end-stage renal disease, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: GrantFiled: March 6, 2006Date of Patent: April 3, 2012Assignee: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
-
Patent number: 8145317Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: GrantFiled: March 6, 2006Date of Patent: March 27, 2012Assignee: Ardian, Inc.Inventors: Denise Demarais, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
-
Patent number: 8145316Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.Type: GrantFiled: July 25, 2005Date of Patent: March 27, 2012Assignee: Ardian, Inc.Inventors: Mark Deem, Denise Demarais, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark